Tramadol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tramadol: From Pain Management to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Tramadol is an opioid analgesic that is currently marketed in South Africa. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder. There are no clinical trials and no publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain (general pharmacological knowledge; the SAHPRA records provided do not include indication text) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 9 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the Evidence Pack. Tramadol is generally described as a mu-opioid receptor agonist that also inhibits serotonin and norepinephrine reuptake, and it is used for symptomatic pain relief.
Acromesomelic dysplasia, Hunter-Thompson type, is a genetic skeletal dysplasia linked to the CDMP1/GDF5 pathway. No established mechanistic link connects tramadol to this condition. At most, tramadol could offer symptomatic analgesia and would not change the course of the disease. The very high score of 99.99% is a knowledge-graph output and should not be read as evidence of efficacy.
The other top predictions show the same pattern. Most are rare skeletal or connective-tissue conditions (brachyolmia, pseudoachondroplasia, myosclerosis) or juvenile and rheumatoid arthritis variants. All are at evidence level L5, with no trials or literature. Where a link exists at all, it is indirect symptomatic pain relief. Paediatric use of tramadol is also restricted by safety concerns, including CYP2D6 ultra-rapid metabolism and respiratory depression.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Tramadol has 9 SAHPRA registrations. The five main ones are listed below. Approved indication text and manufacturer details were not included in the data provided.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 32/2.9/0652 | Tramahexal | Capsule |
| Reg. No. 44/2.9/0496 | Tramazac SR | Sustained-release tablet (recorded as “Srt”) |
| Reg. No. 36/2.9/0337 | Dolotram 50 | Injection |
| Reg. No. 37/2.9/0532 | Dolotram | Capsule |
| Reg. No. 54/2.9/0185 | Domadol Plus | Tablet |
Available routes are oral (capsule, tablet) and injectable.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note that the Evidence Pack flags paediatric restrictions for tramadol (CYP2D6 ultra-rapid metabolism and respiratory depression). This matters for any use in juvenile-onset conditions among the wider predictions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, and no plausible disease-modifying mechanism links tramadol to this genetic skeletal dysplasia. Safety data from the SAHPRA package insert are also missing, so the candidate cannot progress to safety screening.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (download and parse the PI)
- Mechanism of action data from DrugBank
- Any published or registered clinical evidence for tramadol in this condition
- Approved indication text for the local registrations
- Route compatibility assessment against the needs of the target condition
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.